Oral afimetoran reports a positive Phase 2 lupus signal

Beeline Medicines reported that afimetoran met the Week 48 SRI-4 endpoint across all three doses in a randomized 248-person Phase 2 study, with no new safety signals. Effect sizes, subgroup details, steroid outcomes, and full conference data are still needed before judging clinical importance.